Pacer Advisors Inc. Has $198.93 Million Position in Cencora, Inc. $COR

Pacer Advisors Inc. grew its stake in Cencora, Inc. (NYSE:COR) by 12.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 633,249 shares of the company’s stock after acquiring an additional 71,594 shares during the period. Pacer Advisors Inc.’s holdings in Cencora were worth $198,929,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the stock. ExodusPoint Capital Management LP acquired a new position in Cencora in the 4th quarter valued at $16,487,000. Assetmark Inc. lifted its holdings in shares of Cencora by 57.0% during the fourth quarter. Assetmark Inc. now owns 67,281 shares of the company’s stock worth $22,724,000 after buying an additional 24,431 shares in the last quarter. Impact Partnership Wealth LLC acquired a new stake in shares of Cencora during the first quarter worth $1,170,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Cencora by 162.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 289,370 shares of the company’s stock valued at $97,735,000 after acquiring an additional 179,086 shares during the period. Finally, SEB Asset Management AB bought a new stake in shares of Cencora in the first quarter valued at about $134,139,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

COR has been the topic of several research reports. Robert W. Baird decreased their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Barclays dropped their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research note on Wednesday, June 10th. Evercore set a $360.00 price objective on shares of Cencora in a report on Wednesday, April 8th. Wells Fargo & Company decreased their target price on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Finally, Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $367.75.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler purchased 550 shares of Cencora stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the transaction, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.38% of the company’s stock.

Cencora Stock Performance

COR opened at $312.40 on Monday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The firm has a market cap of $60.78 billion, a P/E ratio of 23.96, a price-to-earnings-growth ratio of 1.73 and a beta of 0.57. The business’s fifty day moving average is $289.36 and its 200-day moving average is $315.41.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the company earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts expect that Cencora, Inc. will post 17.8 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio is 18.40%.

Cencora announced that its Board of Directors has authorized a share buyback plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.